Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exlinkibart - Lyvgen Biopharma

Next Previous
X
Search
Drug Profile

Exlinkibart - Lyvgen Biopharma

Alternative Names: LVGN-6051

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lyvgen Biopharma
  • Developer Lyvgen Biopharma; M. D. Anderson Cancer Center
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Squamous cell cancer
  • Phase I/II Soft tissue sarcoma
  • Phase I Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours; Uveal melanoma
  • No development reported Cancer

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Cancer(Combination therapy, Late-stage disease, Metastatic disease) in China (IV, Infusion)
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease, Monotherapy) in China (IV, Infusion)
  • 21 Jun 2024 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) (NCT06378177)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top